Canadian cardiovascular drug development company Milestone Pharmaceuticals has secured $55m through a series C funding round led by Novo Holdings.

The company plans to use the funds to progress the development of its lead product etripamil into Phase 3. The funds will also be used towards marketing and increasing headcount.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Homology Medicines has secured $83.5m through a series B funding round led by Deerfield Management Company.

The US-based genetic medicines company plans to use the funds to advance the development of its lead candidate AMEnDR™, which is currently in the pre-clinical stage.

"Homology Medicines has secured $83.5m through a series B funding round led by Deerfield Management Company."

Ultragenyx Pharmaceutical plans to issue common stock shares through a public offering to raise up to $150m.

The US-based clinical-stage biopharmaceutical company plans to use the funds to advance the development of its clinical and pre-clinical products as well as towards working capital and general corporate purposes.

PreciThera has secured C$36m ($28.8m) through a financing round led by Arix Bioscience.

Based in Canada, PreciThera is a biotechnology company focused on the development of orphan bone diseases. The company plans to use the funds to progress its drug candidates into the clinical stage.